



# An efficient synthesis of argemonine, a pavine alkaloid<sup>†</sup>

Somsak Ruchirawat<sup>a,b,c,\*</sup> and Anucha Namsa-aid<sup>b</sup>

<sup>a</sup>Laboratory of Medicinal Chemistry, Chulabhorn Research Institute, Vipavadee Rangsit Highway, Bangkok 10210, Thailand

<sup>b</sup>Department of Chemistry, Mahidol University, Rama 6 Road, Bangkok 10400, Thailand


<sup>c</sup>Programme on Research and Development of Synthetic Drugs,

Institute of Science and Technology for Research and Development, Mahidol University, Salaya Campus, Thailand

Received 30 November 2000; accepted 5 December 2000

**Abstract**—A method for the synthesis of 1,2-dihydroisoquinoline derivatives is described and the conversion of the 1,2-dihydroisoquinoline intermediate to a pavine alkaloid via palladium-induced intramolecular hydroarylation reaction and radical cyclization is presented. © 2001 Elsevier Science Ltd. All rights reserved.

Argemonine is a prototypical member of the pavine alkaloids, a small group of tetracyclic natural products, and contains the tetrahydroisoquinoline core embedded in its skeleton.<sup>1</sup> Recent findings of biological activities of the pavine alkaloids include inhibition of *herpes simplex* virus type 1<sup>2</sup> and inhibitory activity against tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) production.<sup>3</sup>



Argemonine

There are a number of syntheses<sup>1,4</sup> of pavine alkaloids reported, but most involve an acid-catalyzed intramolecular cyclization of the activated aromatic ring with an iminium salt as in the Pictet–Spengler reaction. The drawback of such a procedure is the failure with nonactivated aromatic compounds and the lack of chemoselectivity in the cyclization of unsymmetrical compounds.

We have developed a new synthesis of pavine alkaloids based on the retrosynthetic analysis shown in Scheme 1.


**Keywords:** pavine alkaloid; intramolecular hydroarylation reaction; radical cyclization reaction.

\* Corresponding author. Fax: 66 2 574 0616 or 66 2 247 1222; e-mail: somsak@tubtim.cri.or.th

<sup>†</sup> This work has been taken in part from Namsa-aid, A., M.Sc. Thesis, Mahidol University 1997, and was presented at the 8th Belgian Organic Synthesis Symposium, July 10–14, 2000, Gent, Belgium.

The key steps involve a palladium-induced intramolecular hydroarylation<sup>5</sup> and a radical cyclization<sup>6</sup> of the key halo derivatives of 1-benzyl-*N*-carboethoxy-1,2-dihydroisoquinolines. The intramolecular hydroarylation involves the reduction of the organopalladium complex formed during the carbon–carbon bond formation in the much exploited Heck reaction.<sup>7</sup> We have also developed a new method for the synthesis of the key 1,2-dihydroisoquinoline derivatives. During our investigation a method for the synthesis<sup>8</sup> of this type of compound was reported involving the addition of a benzylstannane to an isoquinoline in the presence of methyl chloroformate in dichloromethane. We found that 1-benzyl-*N*-carboethoxy-1,2-dihydroisoquinolines could be conveniently obtained by the reaction of 1-benzylisoquinoline derivatives with tributyltin hydride. For example, treatment of papaverine **4a** with tributyltin hydride in dichloromethane at room temperature under a nitrogen atmosphere, followed by addition of ethyl chloroformate at  $-78^{\circ}\text{C}$  and warming to room temperature gave a white solid which, after recrystallization from methanol–dichloromethane, provided compound **3a** in 79% yield. Having found a method for the synthesis of 1-benzyl-*N*-carboethoxy-1,2-dihydroisoquinolines, we then began the synthesis of our key intermediate. The synthesis started with bromination of commercially available papaverine **4a** with a solution of bromine in acetic acid at room temperature for 2 h to give 2'-bromopapaverine<sup>9</sup> **4b** in 75% yield.

Application of the tin hydride reduction gave the required product which was recrystallized from methanol–dichloromethane to give compound **3b** as a white solid in 85% yield. It is interesting to note the



**Scheme 1.** Reagents and conditions: (a) i.  $\text{Bu}_3\text{SnH}/\text{CH}_2\text{Cl}_2$ , ii.  $\text{EtOCOCl}/\text{CH}_2\text{Cl}_2$ ,  $-78^\circ\text{C} \rightarrow \text{rt}$  (**3a**, 79%; **3b**, 85%; **3c**, 85%); (b) See Table 1; (c) LAH/THF, reflux 4 h (**1**, 87%).

chemoselective reduction of the iminium intermediate with tributyltin hydride in the presence of the aryl bromide group. Once the key compound **3b** was obtained, we applied the intramolecular hydroarylation cyclization to effect pavine ring formation. The cyclization of **3b** was accomplished using 10–20 mol% of a reactive catalyst formed from  $\text{Pd}(\text{PPh})_4$  in DMF at  $80\text{--}90^\circ\text{C}$  in the presence of sodium formate as a reducing agent. After purification by PLC, *N*-ethoxycarbonylpavine **2**<sup>10</sup> was obtained in 44% yield together with the corresponding reduction product **3a** in 34% yield as shown in entry 1 of Table 1. The yield of the *N*-ethoxycarbonylpavine **2** was increased to 56% when the starting iodo compound **3c** was used instead of the bromo compound **3b** under similar conditions (entry 3, Table 1). The 2'-iodopapaverine **4c** could be conveniently obtained by the reaction of papaverine with iodine and silver trifluoroacetate.<sup>11</sup> The appearance of four aromatic protons as singlets in the NMR spectrum indicated that 2'-iodopapaverine was obtained.

In addition, the radical cyclization using tributyltin hydride and AIBN of compounds **3b** and **3c** was investigated. It was found that the yield of *N*-ethoxycarbonylpavine **2** was only 30% from the cyclization of the bromo compound **3b** under the tributyltin hydride/AIBN conditions. The corresponding reduction product

**3a** was obtained from the reaction in 5% yield. Similarly, the iodo compound **3b** underwent cyclization with tributyltin hydride to afford the pavine **2** in 42% yield together with 10% of the reduction product **6**. The *N*-ethoxycarbonylpavine **2** was reduced by LAH to form the *N*-methylpavine in 87% yield. The physical and spectroscopic data of our synthetic compound are in full agreement with those of argemonine **1**.<sup>4b</sup>

In conclusion, we have devised a new method for the synthesis of pavine alkaloids as illustrated in the synthesis of natural ( $\pm$ )-argemonine. With appropriate introduction of the iodo group, the approach could be used to synthesize both symmetrical and unsymmetrical pavine alkaloids. We found that the palladium-catalyzed reductive intramolecular arylation reaction is very useful and gives better yields than radical cyclization.

### Acknowledgements

We are grateful to the Thailand Research Fund (TRF) for the generous financial support. We acknowledge the facilities in the Department of Chemistry provided by the PERCH programme.

**Table 1.** Intramolecular arylation of 3,4-dihydroisoquinoline derivatives **3a** and **3b** to pavine (**2**)

Entry	Starting material	Conditions	Yield%	
			Comp. <b>2</b>	Comp. <b>3a</b>
1	Compound <b>3b</b>	$\text{Pd}(\text{PPh})_4/\text{DMF}/\text{HCO}_2\text{Na}/\text{reflux}$ 24 h	44	34
2	Compound <b>3b</b>	$\text{Bu}_3\text{SnH}/\text{AIBN}$ , benzene, reflux 10 h	30	5
3	Compound <b>3c</b>	$\text{Pd}(\text{PPh})_4/\text{DMF}/\text{HCO}_2\text{Na}/\text{reflux}$ 24 h	56	15
4	Compound <b>3c</b>	$\text{Bu}_3\text{SnH}/\text{AIBN}$ , benzene reflux 10 h	42	10

## References

- Gozler, B. In *The Alkaloids*; Brossi, A., Ed.; Academic Press: Orlando, 1987; Vol. 31, pp. 317–389.
  - Varadinova, T. L.; Shishkov, S. A.; Ivanovska, N. D.; Velcheva, M. P.; Danghaaghin, S.; Samadangiin, Z.; Yansanghiin, Z. *Phytotherapy Res.* **1996**, *10*, 414–417.
  - Fujiwara, N.; Ueda, Y.; Ohashi, N. *Bioorg. Med. Chem. Lett.* **1996**, *6*, 743–748.
  - (a) Munchhoh, M. J.; Meyers, A. I. *J. Org. Chem.* **1996**, *61*, 4607–4610; (b) Johnson, A. P.; Luke, R. W. A.; Singh, G.; Boa, A. N. *J. Chem. Soc., Perkin Trans. 1* **1996**, 907–913; (c) Pabuccuoglu, V.; Hesse, M. *Heterocycles* **1997**, *45*, 1751–1758.
  - (a) Wolff, S.; Hofmann, M. R. H. *Synthesis* **1988**, 760–763; (b) Hoffmann, M. H. R.; Schmidt, B.; Wolff, S. *Tetrahedron* **1989**, *45*, 6113–6126.
  - For reviews see: (a) Jasperse, C. P.; Curran, D. P.; Fevig, T. L. *Chem. Rev.* **1991**, *91*, 1237; (b) Bowman, W. R.; Bridge, C. F.; Brookes, P. *J. Chem. Soc., Perkin Trans. 1* **2000**, 1–14 and references cited therein.
  - For recent reviews see: (a) Ikeda, M.; El Bialy, S. A. A.; Yakura, T. *Heterocycles* **1999**, *51*, 1957–1970; (b) Amatore, C.; Jutand, A. *Acc. Chem. Res.* **2000**, *33*, 314–321; (c) Beletskaya, I. P.; Cheprakov, A. V. *Chem. Rev.* **2000**, *100*, 3009–3066; (d) Poli, G.; Giambastiani, G.; Heumann, A. *Tetrahedron* **2000**, *56*, 5959–5989.
  - Deline, J. E.; Miller, R. B. *Tetrahedron Lett.* **1998**, *39*, 1721–1724.
  - (a) Hegedus, L. H.; Stiverson, R. K. *J. Am. Chem. Soc.* **1974**, *96*, 3250–3254; (b) Spath, E.; Lang, N. *Chem. Ber.* **1921**, *54*, 3064–3071.
  - Barker, A. C.; Battersby, A. R. *J. Chem. Soc. C* **1967**, *1*, 1317–1323.
  - Iida, H.; Takarai, T.; Kibayashi, C. *J. Chem. Soc., Chem. Commun.* **1977**, 644–645.
- All compounds have been fully characterized. Spectroscopic data of some selected compounds, 1-(2-iodo-4,5-dimethoxybenzyl)-2-ethoxycarbonyl-6,7-dimethoxy-1,2-dihydroisoquinoline **3c**: mp 154–156°C; FT-IR (Nujol) 2926, 1708, 1633, 1227 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.15 (t, 3H, *J*=7.1 Hz), 1.25 (t, 3H, *J*=7.1 Hz), 2.82–3.06 (m, 4H), 3.66 (s, 3H), 3.72 (s, 3H), 3.73 (s, 3H), 3.77 (s, 3H), 3.83 (s, 3H), 3.84 (s, 3H), 3.87 (s, 3H), 3.89 (s, 3H), 4.02 (m, 2H), 4.17 (q, 2H, *J*=7.1 Hz), 5.45 (dd, 1H, *J*=8.4, 5.6 Hz), 5.55 (t, 1H, *J*=7.1 Hz), 5.79, 6.79 (AB q, 2H, *J*<sub>ab</sub>=7.1 Hz), 5.94, 6.96 (AB q, 2H, *J*<sub>ab</sub>=7.1 Hz), 6.23 (s, 1H), 6.34 (s, 1H), 6.40 (s, 1H), 6.48 (s, 1H), 6.60 (s, 1H), 6.64 (s, 1H), 7.17 (s, 1H), 7.23 (s, 1H). <sup>13</sup>C NMR (100 MHz) δ 14.28, 14.53, 43.78, 44.23, 55.20, 55.71, 55.82, 55.92, 55.97, 56.05, 56.24, 61.99, 62.19, 88.89, 89.60, 107.90, 108.03, 108.39, 108.95, 109.85, 110.23, 113.42, 113.69, 121.24, 121.34, 122.70, 123.15, 123.53, 123.56, 123.75, 124.30, 132.51, 132.61, 147.70, 147.78, 148.07, 148.52, 148.75, 148.96, 152.81, 153.54. FABMS 540 (M<sup>+</sup>+1, 2.24), 413 (8.16), 262 (100.00). Anal. calcd for C<sub>23</sub>H<sub>26</sub>NO<sub>6</sub>I: C, 51.19; H, 4.86; N, 2.63; Found: C, 50.99; H, 4.82; N, 2.41. *N*-Ethoxycarbonylpavine **2**: mp 190–192°C (lit.<sup>10</sup> mp 183–184°C); FT-IR (KBr) 1686, 1519, 1463, 1254 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.28 (t, 3H, *J*=7.1 Hz), 2.76 (d, 2H, *J*=15.9 Hz), 3.38 (dd, 1H, *J*=15.9, 5.6 Hz), 3.42 (dd, 1H, *J*=15.9, 5.6 Hz), 3.77 (s, 3H), 3.78 (s, 3H), 3.85 (s, 3H), 3.87 (s, 3H), 4.11–4.25 (m, 2H), 5.42 (d, 1H, *J*=5.6 Hz), 5.52 (d, 1H, *J*=5.6 Hz), 6.45 (s, 1H), 6.48 (s, 1H), 6.66 (s, 1H), 6.67 (s, 1H). <sup>13</sup>C NMR (100 MHz) δ 14.65, 35.78, 36.04, 48.97, 49.70, 55.64, 55.89, 61.38, 108.97, 109.20, 111.47, 111.65, 123.95, 124.48, 128.78, 129.08, 147.45, 147.96, 148.05, 154.21. EI-MS 413 (M<sup>+</sup>, 17.50), 412 (4.89), 340 (8.25), 278 (6.84), 262 (52.36), 28 (100.00). Anal. calcd for C<sub>26</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub>: C, 66.40; H, 6.59; N, 3.48. Found: C, 66.24; H, 6.46; N, 3.73.